Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1997 1
1999 2
2000 1
2001 2
2002 1
2003 1
2004 1
2006 2
2007 4
2008 1
2009 5
2010 9
2011 4
2012 2
2013 6
2014 4
2015 6
2016 5
2017 4
2018 5
2019 7
2020 8
2021 11
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Pujade-Lauraine E, et al. Among authors: witteveen p. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637997 Clinical Trial.
Pan-cancer whole-genome analyses of metastatic solid tumours.
Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E. Priestley P, et al. Among authors: witteveen po. Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23. Nature. 2019. PMID: 31645765 Free PMC article.
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H. Kopper O, et al. Among authors: witteveen po. Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011202
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ, Espejo Valle-Inclan J, Hami N, Lõhmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H, Kloosterman WP, Cuppen E, Snippert HJG, Zweemer RP, Witteveen PO, Stelloo E. de Witte CJ, et al. Among authors: witteveen po. Cell Rep. 2020 Jun 16;31(11):107762. doi: 10.1016/j.celrep.2020.107762. Cell Rep. 2020. PMID: 32553164 Free article.
Tamoxifen and pregnancy: an absolute contraindication?
Schuurman TN, Witteveen PO, van der Wall E, Passier JLM, Huitema ADR, Amant F, Lok CAR. Schuurman TN, et al. Among authors: witteveen po. Breast Cancer Res Treat. 2019 May;175(1):17-25. doi: 10.1007/s10549-019-05154-7. Epub 2019 Feb 1. Breast Cancer Res Treat. 2019. PMID: 30707336 Review.
Predicting Anxiety in Hospitalized Cancer Patients.
van den Brekel L, van der Baan FH, Zweers D, Koldenhof JJ, Vos JBH, de Graeff A, Witteveen PO, Teunissen SCCM. van den Brekel L, et al. Among authors: witteveen po. J Pain Symptom Manage. 2020 Sep;60(3):522-530.e1. doi: 10.1016/j.jpainsymman.2020.04.005. Epub 2020 Apr 16. J Pain Symptom Manage. 2020. PMID: 32305577 Free article.
[The clinical perspective of angiogenesis inhibitors].
Radema SA, Witteveen PO, Gebbink MB, Voest EE. Radema SA, et al. Among authors: witteveen po. Ned Tijdschr Geneeskd. 2003 Aug 30;147(35):1675-80. Ned Tijdschr Geneeskd. 2003. PMID: 14513538 Review. Dutch.
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, Lopez-Yurda M, Beijnen JH, Huitema ADR, Witteveen PO, Steeghs N, van Haaften G, van Vugt MATM, de Ridder J, Opdam FL. Embaby A, et al. Among authors: witteveen po. Gynecol Oncol. 2023 Jul;174:239-246. doi: 10.1016/j.ygyno.2023.05.063. Epub 2023 May 24. Gynecol Oncol. 2023. PMID: 37236033 Clinical Trial.
90 results